CRBP vs. MRSN, ANNX, BMEA, HRTX, ANRO, KRRO, AMRN, LXRX, ADCT, and NGNE
Should you be buying Corbus Pharmaceuticals stock or one of its competitors? The main competitors of Corbus Pharmaceuticals include Mersana Therapeutics (MRSN), Annexon (ANNX), Biomea Fusion (BMEA), Heron Therapeutics (HRTX), Alto Neuroscience (ANRO), Korro Bio (KRRO), Amarin (AMRN), Lexicon Pharmaceuticals (LXRX), ADC Therapeutics (ADCT), and Neurogene (NGNE). These companies are all part of the "pharmaceutical preparations" industry.
Corbus Pharmaceuticals (NASDAQ:CRBP) and Mersana Therapeutics (NASDAQ:MRSN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, community ranking, dividends, earnings, institutional ownership and profitability.
Corbus Pharmaceuticals has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -352.01%. Corbus Pharmaceuticals' return on equity of -135.17% beat Mersana Therapeutics' return on equity.
Corbus Pharmaceuticals has higher earnings, but lower revenue than Mersana Therapeutics. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks.
64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.9% of Mersana Therapeutics shares are owned by institutional investors. 4.0% of Corbus Pharmaceuticals shares are owned by insiders. Comparatively, 12.5% of Mersana Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Corbus Pharmaceuticals has a beta of 2.46, meaning that its share price is 146% more volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.
Corbus Pharmaceuticals currently has a consensus price target of $61.00, suggesting a potential upside of 41.89%. Mersana Therapeutics has a consensus price target of $6.29, suggesting a potential upside of 140.83%. Given Mersana Therapeutics' higher possible upside, analysts plainly believe Mersana Therapeutics is more favorable than Corbus Pharmaceuticals.
In the previous week, Mersana Therapeutics had 1 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 13 mentions for Mersana Therapeutics and 12 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 0.55 beat Mersana Therapeutics' score of 0.50 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media.
Corbus Pharmaceuticals received 185 more outperform votes than Mersana Therapeutics when rated by MarketBeat users. Likewise, 66.62% of users gave Corbus Pharmaceuticals an outperform vote while only 65.78% of users gave Mersana Therapeutics an outperform vote.
Summary
Corbus Pharmaceuticals and Mersana Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Corbus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corbus Pharmaceuticals Competitors List
Related Companies and Tools
